Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.65 |
| ▸ | MAOA | P21397 | 6/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | SDHA | P31040 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CALML3 | P27482 | 1/20 | 0.65 |
| ▸ | F10 | P00742 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114899 | 1.00 | MAOB (0.65) | MAOBMAOAPTGS1SDHALMNA | |
| Hydrochloric Acid SCHEMBL2591252 | 0.99 | MAOB (0.64) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL28110355 | 0.91 | MAOB (0.53) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL28673553 | 0.87 | F10 (0.56) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10038920 | 0.87 | MAOB (0.60) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3574462 | 0.86 | MAOB (0.52) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL17026089 | 0.85 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL10038450 | 0.85 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12478380 | 0.85 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL19827376 | 0.84 | MAOB (0.78) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106279054-A | Linezolid and the new preparation process of new intermediate thereof | 李药业有限公司 | 2017-01-04 | — | — | CN | claimed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | claimed |
| EP-2595968-B1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LTD (IN) | 2015-09-09 | — | — | EP | claimed |
| US-20130324719-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LIMITED (IN) | 2013-12-05 | — | — | US | claimed |
| EP-2595968-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | Lee Pharma Limited (IN) | 2013-05-29 | — | — | EP | claimed |
| WO-2012114355-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LIMITED (IN) | 2012-08-30 | — | — | WO | claimed |
| WO-2004026848-A1 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS | LUPIN LIMITED (IN) | 2004-04-01 | — | — | WO | claimed |
| CN-106279054-A | Linezolid and the new preparation process of new intermediate thereof | 李药业有限公司 | 2017-01-04 | — | — | CN | disclosed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| EP-2595968-B1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| US-20130324719-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LIMITED (IN) | 2013-12-05 | — | — | US | disclosed |
| US-20130324719-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LIMITED (IN) | 2013-12-05 | — | — | US | disclosed |
| CN-103391927-A | Novel preparation method of linezolid and novel intermediate thereof | LEE PHARMA LTD | 2013-11-13 | — | — | CN | disclosed |
| EP-2595968-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | Lee Pharma Limited (IN) | 2013-05-29 | — | — | EP | disclosed |
| EP-2595968-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | Lee Pharma Limited (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012114355-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LIMITED (IN) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012114355-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LIMITED (IN) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324719-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | HDAC1, HDAC3, HDAC6 | MAOB 1022/4885MAOA 891/4885PTGS1 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.